Alnylam Pharmaceuticals, Inc. (ALNY) Social Stream



Alnylam Pharmaceuticals, Inc. (ALNY): $136.41

-1.90 (-1.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALNY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 459

in industry

Featured Post From StockTwits About ALNY

$ALNY New Press Release:

Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function. Lumasiran is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – that is being investigated for the treatment of adult and pediatric p (...)

https://wchr.one/96620
WebChronicleToday, published July 29, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4919 seconds.